Document:

Executive Employment Agreement - Ivan P. Gergel

 Exhibit 10.122 
 Execution Version 
 ENDO PHARMACEUTICALS HOLDINGS INC. 

EXECUTIVE EMPLOYMENT AGREEMENT 
 THIS AGREEMENT (the “Agreement”) is hereby entered into as of the 27th day of October, 2011 (the “Effective Date”), by and between Endo Pharmaceuticals Holdings Inc. (the
“Company”) and Ivan P. Gergel (the “Executive”) (hereinafter collectively referred to as “the parties”). 
 In consideration of the respective agreements of the parties contained herein, it is agreed as follows: 
  

	1.	Term; Effect on Original Agreement. 

  

	 	(a)	The term of this Agreement shall be for the period commencing on the Effective Date and ending, subject to earlier termination as set forth in Section 6, on the
third anniversary of the Effective Date (the “Employment Term”). 

  

	 	(b)	As of the Effective Date, Executive’s Employment Agreement with the Company, effective as of April 29, 2008 (the “Original Agreement”) shall be
superseded in its entirety by this Agreement, and the Original Agreement shall thereupon have no further force and effect. For the avoidance of doubt, Executive agrees that he shall not be entitled to any payments or benefits under the Original
Agreement on or following the Effective Date. 

  

	2.	Employment. During the Employment Term: 

  

	 	(a)	Executive will have such duties as are assigned or delegated to Executive by the Chief Executive Officer, and will serve as Executive Vice President, Research and
Development and Chief Scientific Officer of the Company. 

  

	 	(b)	 Executive shall devote his full-time attention to the business and affairs of the Company. Executive may serve on corporate, civil or charitable boards
or committees, subject in all cases to the approval of the Nominating and Governance Committee of the Company’s board of directors (the “Board”) and the Chief Executive Officer of the Company. Executive may manage personal and family
investments, participate in industry organizations and deliver lectures at 

  
 1 

	 	
educational institutions, so long as such activities do not interfere with the performance of Executive’s responsibilities hereunder. 

 

	 	(c)	Executive shall be subject to and shall abide by each of the Company’s personnel policies applicable and communicated in writing to senior executives.

  

	3.	Annual Compensation. 

  

	 	(a)	Base Salary. The Company agrees to pay or cause to be paid to Executive during the Employment Term a base salary at the rate of $636,000 per annum or such
increased amount as the Board may from time to time determine (hereinafter referred to as the “Base Salary”). Such Base Salary shall be payable in accordance with the Company’s customary practices applicable to its executives. Such
Base Salary, upon a recommendation by the Chief Executive Officer, shall be reviewed at least annually by the Board or by the Compensation Committee of the Board (the “Committee”), and may be increased in the sole discretion of the
Committee, but not decreased. 

  

	 	(b)	Incentive Compensation. For each fiscal year of the Company ending during the Employment Term, beginning with the 2011 fiscal year, Executive shall have a target
annual cash bonus opportunity equal to 55% of the Base Salary (such target bonus, as may hereafter be increased, the “Target Bonus”). The actual bonus, if any, paid to Executive may be more or less than the Target Bonus and shall be
payable based upon the achievement of certain performance targets set by the Committee in its sole discretion, taking into account the recommendation of the Chief Executive Officer, or such other criteria so established by the Committee. Such annual
cash bonus (“Incentive Compensation”) shall be paid in no event later than the 15th day of the third month following the end of the taxable year (of the Company or Executive, whichever is later) in which the performance targets have been
achieved. 

  

	4.	Long-Term Compensation. To the extent the Company determines to award stock options, restricted stock units or other similar consideration to management
personnel based upon duration of employment or achievement of performance targets, or both, Executive shall be permitted to participate in such programs. For each fiscal year or part thereof during the Employment Term, Executive shall be eligible to
receive equity-based compensation in a targeted amount equal to two hundred percent (200%) of the Base Salary for such fiscal year (or such lesser (including zero) or greater percent of the Base Salary for such fiscal year as is recommended in
good faith to the Committee by the Chief Executive Officer of the Company and approved by the Committee). All such equity-based awards shall be subject to the terms and conditions set forth in the applicable plan and agreements, and in all cases
shall be as determined by the Committee. 

  
 2 

	5.	Other Benefits. 

  

	 	(a)	Employee Benefits. During the Employment Term, Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by the
Company and made available to employees generally, including, without limitation, all pension, retirement, profit sharing, savings, medical, hospitalization, disability, dental, life or travel accident insurance benefit plans, to the extent
Executive is eligible under the terms of such plans. Executive’s participation in such plans, practices and programs shall be on the same basis and terms as are applicable to employees of the Company generally. 

 

	 	(b)	Executive Benefits. During the Employment Term, Executive shall be entitled to participate in all executive benefit or incentive compensation plans now
maintained or hereafter established by the Company for the purpose of providing compensation and/or benefits to comparable executive employees of the Company including, but not limited to, the Company’s deferred compensation plans and any
supplemental retirement, deferred compensation, supplemental medical or life insurance or other bonus or incentive compensation plans. Unless otherwise provided herein, Executive’s participation in such plans shall be on the same basis and
terms, as other senior executives of the Company. No additional compensation provided under any of such plans shall be deemed to modify or otherwise affect the terms of this Agreement or any of Executive’s entitlements hereunder.

  

	 	(c)	Fringe Benefits and Perquisites. During the Employment Term, Executive shall be entitled to all fringe benefits and perquisites generally made available by the
Company to its senior executives. For the avoidance of doubt, Executive shall not be entitled to any excise tax gross-up under Section 280G or Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”) (or any
successor provisions) or any other tax gross-up. 

  

	 	(d)	Business Expenses. Upon submission of proper invoices in accordance with the Company’s normal procedures, Executive shall be entitled to receive prompt
reimbursement of all reasonable out-of-pocket business, entertainment and travel expenses incurred by Executive in connection with the performance of Executive’s duties hereunder and incurred in accordance with the Company’s travel and
entertainment policy in effect from time to time. Such reimbursement shall be made in no event later than the end of the calendar year following the calendar year in which the expenses were incurred. 

 

	 	(e)	 Office and Facilities. During the Employment Term Executive shall be provided with an appropriate office at the Company’s headquarters,
with such secretarial and other support facilities as are commensurate with Executive’s status with the 

  
 3 

	 	
Company, which facilities shall be adequate for the performance of Executive’s duties hereunder. 

 

	 	(f)	Motor Vehicle Allowance. During the Employment Term, Executive will be entitled to use of an automobile, mutually acceptable to Executive and the Company. The
Company will reimburse Executive for all operating expenses relating thereto upon Executive’s submission of appropriate documentation as set forth in Section 5(d). The Company will determine the actual value, if any, of Executive’s
non-business use of such automobile and will furnish Executive with a W-2 Wage and Tax Statement to be included in Executive’s income tax returns, in accordance with prevailing Internal Revenue Service regulations. 

 

	 	(g)	Vacation and Sick Leave. Executive shall be entitled, without loss of pay, to absent himself voluntarily from the performance of Executive’s employment
under this Agreement, pursuant to the following: 

  

	 	(i)	Executive shall be entitled to annual vacation in accordance with the vacation policies of the Company as in effect from time to time, which shall in no event be less
than four weeks per year; vacation must be taken at such time or times as approved by the Board; and 

  

	 	(ii)	Executive shall be entitled to sick leave (without loss of pay) in accordance with the Company’s policies as in effect from time to time. 

 

	6.	Termination. The Employment Term and Executive’s employment hereunder may be terminated under the circumstances set forth below; provided, however, that
notwithstanding anything contained herein to the contrary, Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement unless Executive would be considered to have incurred a “separation from
service” from the Company within the meaning of Section 409A of the Code. 

  

	 	(a)	 Disability. The Company may terminate Executive’s employment, on written notice to Executive after having reasonably established
Executive’s Disability. For purposes of this Agreement, Executive will be deemed to have a “Disability” if, as a result of any medically determinable physical or mental impairment that can be expected to result in death or can be
expected to last for a continuous period of not less than twelve (12) months, Executive is unable to perform the core functions of Executive’s position (with or without reasonable accommodation) or is receiving income replacement benefits
for a period of three months or more under an accident and health plan covering employees of the Company. Executive shall be entitled to the compensation and benefits provided for under this Agreement for any period prior to Executive’s
termination by reason of 

  
 4 

	 	
Disability during which Executive is unable to work due to a physical or mental infirmity in accordance with the Company’s policies for similarly-situated executives.

  

	 	(b)	Death. Executive’s employment shall be terminated as of the date of Executive’s death. 

 

	 	(c)	Cause. The Company may terminate Executive’s employment for “Cause,” effective as of the date of the Notice of Termination (as defined in
Section 7 below). “Cause” shall mean, for purposes of this Agreement: (a) the continued failure by Executive substantially to perform Executive’s duties under this Agreement (other than any such failure resulting from
Disability), (b) the criminal felony indictment of Executive by a court of competent jurisdiction, (c) the engagement by Executive in misconduct that has caused, or in the good faith judgment of the Chief Executive Officer may cause if not
discontinued, harm (financial or otherwise) to the Company or any of its subsidiaries, if any, such harm to include, without limitation, (i) the disclosure of material secret or Confidential Information (as defined in Section 11(d)) of the
Company or any of its subsidiaries, if any, (ii) the debarment of the Company or any of its subsidiaries, if any, by the U.S. Food and Drug Administration or any successor agency (the “FDA”), or (iii) the registration of the
Company or any of its subsidiaries, if any, with the U.S. Drug Enforcement Administration of any successor agency (the “DEA”) to be revoked, (d) the debarment of Executive by the FDA, or (e) the continued material breach by
Executive of this Agreement. Notwithstanding the foregoing, prior to having “Cause” for Executive’s termination (other than as described in clauses (b) and (d) thereof), the Company must deliver a written demand to Executive
which specifically identifies the conduct that may provide grounds for Cause, and Executive must have failed to cure such conduct (if curable) within fifteen (15) days after such demand. Reference in this paragraph to the Company shall also
include direct and indirect subsidiaries of the Company. 

  

	 	(d)	Without Cause. The Company may terminate Executive’s employment without Cause. The Company shall deliver to Executive a Notice of Termination (as defined in
Section 7 below) not less than thirty (30) days prior to the termination of Executive’s employment without Cause and the Company shall have the option of terminating Executive’s duties and responsibilities prior to the expiration
of such thirty-day notice period. 

  

	 	(e)	 Good Reason. Executive may terminate employment with the Company for Good Reason (as defined below) by delivering to the Company a Notice of
Termination (as defined in Section 7 below) not less than thirty (30) days prior to the termination of Executive’s employment for Good Reason. The Company shall have the option of terminating Executive’s duties and
responsibilities prior to the 

  
 5 

	 	
expiration of such thirty-day notice period. For purposes of this Agreement, “Good Reason” means any of the following: (a) a material diminution in Executive’s salary or
benefits; (b) the assignment of Executive without Executive’s consent to a position, responsibilities, or duties of a materially lesser status or degree of responsibility than Executive’s position, responsibilities, or duties
immediately following the Effective Date; (c) any material breach by the Company of its obligations under this Agreement (including, without limitation, Section 5); or (d) the Company requiring Executive to be based at any office or
location more than fifty (50) miles from Executive’s current principal business location (except for any such change in location which is not materially adverse to Executive). Executive shall provide notice of the existence of the Good
Reason condition within ninety (90) days of the date Executive learns of the condition, and the Company shall have a period of thirty (30) days during which it may remedy the condition, and in case of full remedy such condition shall not
be deemed to constitute Good Reason hereunder. 

  

	 	(f)	Without Good Reason. Executive may voluntarily terminate Executive’s employment without Good Reason by delivering to the Company a Notice of Termination not
less than thirty (30) days prior to the termination of Executive’s employment and the Company shall have the option of terminating Executive’s duties and responsibilities prior to the expiration of such thirty-day notice period.

  

	7.	Notice of Termination. Any purported termination by the Company or by Executive shall be communicated by written Notice of Termination to the other party hereto.
For purposes of this Agreement, a “Notice of Termination” shall mean a notice that indicates a termination date, the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and
circumstances claimed to provide a basis for termination of Executive’s employment under the provision so indicated. For purposes of this Agreement, no such purported termination of Executive’s employment hereunder shall be effective
without such Notice of Termination (unless waived by the party entitled to receive such notice). 

  

	8.	Compensation Upon Termination. Upon termination of Executive’s employment during the Employment Term, Executive shall be entitled to the following benefits:

  

	 	(a)	Termination by the Company for Cause or by Executive Without Good Reason. If Executive’s employment is terminated by the Company for Cause or by Executive
without Good Reason, the Company shall pay Executive all amounts earned or accrued hereunder through the termination date, including: 

  

	 	(i)	any accrued and unpaid Base Salary; 

  
 6 

	 	(ii)	any Incentive Compensation earned but unpaid in respect of any completed fiscal year preceding the termination date; 

 

	 	(iii)	reimbursement for any and all monies advanced or expenses incurred in connection with Executive’s employment for reasonable and necessary expenses incurred by
Executive on behalf of the Company for the period ending on the termination date; 

  

	 	(iv)	any accrued and unpaid vacation pay; 

  

	 	(v)	any previous compensation that Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the
applicable deferred compensation plans or arrangements then in effect, to the extent vested as of Executive’s termination date; and 

  

	 	(vi)	any amount or benefit as provided under any benefit plan or program in accordance with the terms thereof; (the foregoing items in Sections 8(a)(i) through 8(a)(vi)
being collectively referred to as the “Accrued Compensation”). 

  

	 	(b)	Termination by the Company for Disability. If Executive’s employment is terminated by the Company for Disability, the Company shall pay or provide to
Executive: 

  

	 	(i)	the Accrued Compensation; 

  

	 	(ii)	an amount equal to the Incentive Compensation that Executive would have been entitled to receive in respect of the fiscal year in which Executive’s termination
date occurs, had Executive continued in employment until the end of such fiscal year, which amount, determined based on the Company’s actual performance for such year relative to the performance goals applicable to Executive, shall be
multiplied by a fraction (A) the numerator of which is the number of days in such fiscal year through termination date and (B) the denominator of which is 365 (the “Pro-Rata Bonus”) and shall be payable in a lump sum payment at
the time such bonus or incentive awards are payable to other participants; and 

  

	 	(iii)	 continued coverage for Executive and Executive’s dependents under any health, medical, dental, vision or life insurance program or policy in which
Executive was eligible to participate as of the time of Executive’s 

  
 7 

	 	
employment termination, for two (2) years following such termination on terms no less favorable to Executive and Executive’s dependents (including with respect to payment for the costs
thereof) than those in effect immediately prior to such termination, which coverage shall become secondary to any coverage provided to Executive by a subsequent employer and to any Medicare coverage for which Executive becomes eligible. After such
two-year period, Executive and Executive’s dependents who are qualified beneficiaries shall be entitled, at Executive’s election and cost, to eighteen (18) months of continuation coverage at COBRA rates. 

Further, upon Executive’s Disability (irrespective of any termination of employment related thereto), the Company shall pay
Executive for twenty-four (24) consecutive months thereafter regular payments in the amount by which the monthly Base Salary exceeds Executive’s monthly Disability insurance benefit. 

 

	 	(c)	Termination By Reason of Death. If Executive’s employment is terminated by reason of Executive’s death, the Company shall pay or provide to
Executive’s beneficiaries: 

  

	 	(i)	the Accrued Compensation; 

  

	 	(ii)	the Pro-Rata Bonus; and 

  

	 	(iii)	continued coverage for Executive’s dependents under any health, medical, dental, vision or life insurance program or policy in which Executive was eligible to
participate as of the time of Executive’s employment termination, for two (2) years following such termination on terms no less favorable to Executive’s dependents (including with respect to payment for the costs thereof) than those
in effect immediately prior to such termination. After such two-year period, Executive’s dependents who are qualified beneficiaries shall be entitled, at their election and cost, to eighteen (18) months of continuation coverage at COBRA
rates. 

  

	 	(d)	Termination by the Company Other Than for Cause, Disability or Death, or by Executive for Good Reason. If Executive’s employment by the Company shall be
terminated by the Company other than for Cause, Disability or death, or by Executive for Good Reason, then, subject to Section 15(f) of the Agreement, Executive shall be entitled to the benefits provided in this Section 8(d):

  

	 	(i)	the Company shall pay to Executive the Accrued Compensation; 

  
 8 

	 	(ii)	the Company shall pay to Executive the Pro-Rata Bonus; 

  

	 	(iii)	the Company shall pay to Executive as severance pay and in lieu of any further Base Salary or other compensation and benefits for periods subsequent to the termination
date, an amount in cash, which amount shall be payable in a lump sum payment within sixty (60) days following such termination (subject to Section 10), equal to two (2) times the sum of (A) Executive’s Base Salary and
(B) the Target Bonus; and 

  

	 	(iv)	the Company shall provide Executive with continued coverage under any health, medical, dental, vision or life insurance program or policy in which Executive was
eligible to participate as of the time of Executive’s employment termination for two (2) years following such termination on terms no less favorable to Executive and Executive’s dependents (including with respect to payment for the
costs thereof) than those in effect immediately prior to such termination, which coverage shall become secondary to any coverage provided to Executive by a subsequent employer and to any Medicare coverage for which Executive becomes eligible. After
such two-year period, Executive and Executive’s dependents who are qualified beneficiaries shall be entitled, at Executive’s election and cost, to eighteen (18) months of continuation coverage at COBRA rates. 

 

	 	(e)	No Mitigation. Executive shall not be required to mitigate the amount of any payment provided for under this Section 8 by seeking other employment or
otherwise and, except as provided in Sections 8(b)(iii) and 8(d)(iv) above, no such payment shall be offset or reduced by the amount of any compensation or benefits provided to Executive in any subsequent employment. 

 

	9.	Golden Parachute Tax. If any payment or benefit to be made or provided to or for the benefit of Executive (including any payment or benefit received pursuant to
this Agreement or otherwise) would be (in whole or in part) subject to the excise tax imposed by Section 4999 of the Code, or any successor provision thereto, or any similar tax imposed by state or local law, or any interest or penalties with
respect to such excise tax (such tax or taxes, together with any such interest and penalties, are hereafter collectively referred to as the “Excise Tax”), then, the payments and benefits provided hereunder shall be reduced in the manner
selected by Executive to the extent necessary to make such payments and benefits not subject to such Excise Tax (provided that cash payments that do not constitute deferred compensation within the meaning of Section 409A of the Code shall be
reduced first), but only if such reduction results in a higher after-tax payment to Executive after taking into account the Excise Tax and any additional taxes Executive would pay if such payments and benefits were not reduced.

  
 9 

	10.	Section 409A. If any payments or benefits due to Executive hereunder would cause the application of an accelerated or additional tax under Section 409A
of the Code (“Section 409A”), such payments or benefits shall be restructured in a manner which does not cause such an accelerated or additional tax. Without limiting the foregoing and notwithstanding anything contained herein to the
contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A, (i) amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during
the six-month period immediately following Executive’s separation from service shall instead be paid on the first business day after the date that is six months following Executive’s termination date (or death, if earlier), with interest
from the date such amounts would otherwise have been paid at the short-term applicable federal rate, compounded semi-annually, as determined under Section 1274 of the Code for the month in which payment would have been made but for the delay in
payment required to avoid the imposition of an additional rate of tax on Executive under Section 409A, and (ii) each amount to be paid or benefit to be provided under this Agreement shall be construed as a separately identified payment for
purposes of Section 409A. 

  

	11.	Records and Confidential Data. 

  

	 	(a)	Executive acknowledges that in connection with the performance of Executive’s duties during the Employment Term, the Company will make available to Executive, or
Executive will develop and have access to, certain Confidential Information (as defined below) of the Company and its subsidiaries. Executive acknowledges and agrees that any and all Confidential Information learned or obtained by Executive during
the course of Executive’s employment by the Company or otherwise, whether developed by Executive alone or in conjunction with others or otherwise, shall be and is the property of the Company and its subsidiaries. 

 

	 	(b)	Except to the extent required to be disclosed at law or pursuant to judicial process or administrative subpoena, the Confidential Information will be kept confidential
by Executive, will not be used in any manner that is detrimental to the Company, will not be used other than in connection with Executive’s discharge of Executive’s duties hereunder, and will be safeguarded by Executive from unauthorized
disclosure. 

  

	 	(c)	 Following the termination of Executive’s employment hereunder, as soon as possible after the Company’s written request, Executive will return
to the Company all written Confidential Information that has been provided to Executive and Executive will destroy all copies of any analyses, compilations, studies or other documents prepared by Executive or for Executive’s use containing or
reflecting any Confidential Information. Within five (5) business days of the receipt of such request by Executive, Executive shall, upon written request of the Company, deliver to the Company a document certifying that such

  
 10 

	 	
written Confidential Information has been returned or destroyed in accordance with this Section 11(c). 

 

	 	(d)	For the purposes of this Agreement, “Confidential Information” shall mean all confidential and proprietary information of the Company and its subsidiaries,
including, without limitation, 

  

	 	(i)	trade secrets concerning the business and affairs of the Company and its subsidiaries, product specifications, data, know-how, formulae, compositions, processes,
non-public patent applications, designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current, and planned research and development, current and planned manufacturing or distribution methods and processes, customer
lists, current and anticipated customer requirements, price lists, market studies, business plans, computer software and programs (including object code and source code), computer software and database technologies, systems, structures, and
architectures (and related formulae, compositions, processes, improvements, devices, know-how, inventions, discoveries, concepts, ideas, designs, methods and information); 

 

	 	(ii)	information concerning the business and affairs of the Company and its subsidiaries (which includes unpublished financial statements, financial projections and budgets,
unpublished and projected sales, capital spending budgets and plans, the names and backgrounds of key personnel, to the extent not publicly known, personnel training and techniques and materials) however documented; and 

 

	 	(iii)	notes, analysis, compilations, studies, summaries, and other material prepared by or for the Company or its subsidiaries containing or based, in whole or in part, on
any information included in the foregoing. For purposes of this Agreement, the Confidential Information shall not include and Executive’s obligation’s shall not extend to (i) information that is generally available to the public,
(ii) information obtained by Executive other than pursuant to or in connection with this employment and (iii) information that is required to be disclosed by law or legal process. 

 

	 	(e)	Executive’s obligations under this Section 11 shall survive the termination of the Employment Term. 

  
 11 

	12.	Covenant Not to Solicit, Not to Compete, Not to Disparage and to Cooperate in Litigation. 

 

	 	(a)	Covenant Not to Solicit. To protect the Confidential Information and other trade secrets of the Company as well as the goodwill and competitive business of the
Company, Executive agrees, during the Employment Term and for a period of twenty-four (24) months after Executive’s cessation of employment with the Company, not to solicit or participate in or assist in any way in the solicitation of any
employees of the Company. For purposes of this covenant, “solicit” or “solicitation” means directly or indirectly influencing or attempting to influence employees of the Company to cease employment with the Company or to become
employed with any other person, partnership, firm, corporation or other entity. Executive agrees that the covenants contained in this Section 12(a) are reasonable and desirable to protect the Confidential Information of the Company, provided,
that solicitation through general advertising not targeted at the Company’s employees or the provision of references shall not constitute a breach of such obligations. 

 

	 	(b)	Covenant Not to Compete. 

  

	 	(i)	To protect the Confidential Information and other trade secrets of the Company as well as the goodwill and competitive business of the Company, Executive agrees, during
the Employment Term and for a period of twenty-four (24) months after Executive’s cessation of employment with the Company, that Executive will not, except in the course of Executive’s employment hereunder, directly or indirectly
manage, operate, control, or participate in the management, operation, or control of, be employed by, associated with, or in any manner connected with, lend Executive’s name to, or render services or advice to, any third party or any business
whose products compete (including as described below) in whole or in part with the products (both on market and in development) of the Company (disregarding any non-pain management products that were not products promoted by the Company during the
last three years); provided, however, that Executive may in any event (w) own up to a 5% passive ownership interest in any public or private entity, (x) be employed by, or otherwise have a material association with, any business whose
products compete with the material products of the Company so long as his employment or association is with a separately managed and operated division or affiliate of such business that does not compete with the Company, and (y) serve on the
board of any business whose products compete with the Company as an immaterial part of its overall business, provided that he recuses himself fully and completely from all matters relating to such products. 

  
 12 

	 	(ii)	For purposes of this Section 12(b), any third party or any business whose products compete includes any entity with which the Company has had a product(s)
licensing agreement during the Employment Term and any entity with which the Company is at the time of termination actively negotiating, and eventually concludes within twelve (12) months of the Employment Term, a commercial agreement.

  

	 	(c)	Nondisparagement. Executive covenants that during and following the Employment Term, Executive will not disparage or encourage or induce others to disparage the
Company or its subsidiaries, together with all of their respective past and present directors and officers, as well as their respective past and present managers, officers, shareholders, partners, employees, agents, attorneys, servants and customers
and each of their predecessors, successors and assigns (collectively, the “Company Entities and Persons”); provided that such limitation shall extend to past and present managers, officers, shareholders, partners, employees, agents,
attorneys, servants and customers only in their capacities as such or in respect of their relationship with the Company and its subsidiaries. The Company agrees that, during and following the Employment Term, neither the Company nor any director or
officer, will issue any written statement that disparages Executive or encourages or induces others to disparage Executive. The term “disparage” includes, without limitation, comments or statements adversely affecting in any manner
(i) the conduct of the business of the Company Entities and Persons or Executive, or (ii) the business reputation of the Company Entities and Persons or Executive. Nothing in this Agreement is intended to or shall prevent either party from
providing, or limiting testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law. 

 

	 	(d)	 Cooperation in Any Investigations and Litigation. Executive agrees that Executive will reasonably cooperate with the Company, and its counsel,
in connection with any investigation, inquiry, administrative proceeding or litigation relating to any matter in which Executive was involved or of which Executive has knowledge as a result of Executive’s service with the Company by providing
truthful information. The Company agrees to promptly reimburse Executive for reasonable expenses reasonably incurred by Executive, in connection with Executive’s cooperation pursuant to this Section 12(d). Such reimbursements shall be made
as soon as practicable, and in no event later than the calendar year following the year in which the expenses are incurred. Executive agrees that, in the event Executive is subpoenaed by any person or entity (including, but not limited to, any
government agency) to give testimony (in a deposition, court proceeding or otherwise) which in any way relates to Executive’s employment by the Company, Executive will, to the extent not legally prohibited from doing so, give prompt notice of
such request to the Chief Legal Officer of the Company so that the Company may contest the right of the requesting person or entity to such 

  
 13 

	 	
disclosure before making such disclosure. Nothing in this provision shall require Executive to violate Executive’s obligation to comply with valid legal process. 

 

	 	(e)	Blue Pencil. It is the intent and desire of Executive and the Company that the provisions of this Section 12 be enforced to the fullest extent permissible
under the laws and public policies as applied in each jurisdiction in which enforcement is sought. If any particular provision of this Section 12 shall be determined to be invalid or unenforceable, such covenant shall be amended, without any
action on the part of either party hereto, to delete therefrom the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such
adjudication is made. 

  

	 	(f)	Survive. Executive’s obligations under this Section 12 shall survive the termination of the Employment Term. 

 

	13.	Remedies for Breach of Obligations under Sections 11 or 12 hereof. Executive acknowledges that the Company will suffer irreparable injury, not readily
susceptible of valuation in monetary damages, if Executive breaches Executive’s obligations under Sections 11 or 12 hereof. Accordingly, Executive agrees that the Company will be entitled, in addition to any other available remedies, to obtain
injunctive relief against any breach or prospective breach by Executive of Executive’s obligations under Sections 11 or 12 hereof in any Federal or state court sitting in the State of Delaware, or, at the Company’s election, in any other
state in which Executive maintains Executive’s principal residence or Executive’s principal place of business. Executive hereby submits to the non-exclusive jurisdiction of all those courts for the purposes of any actions or proceedings
instituted by the Company to obtain that injunctive relief, and Executive agrees that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by Executive to the Company, or in
any other manner authorized by law. 

  

	14.	Representations and Warranties. 

  

	 	(a)	The Company represents and warrants that (i) it is fully authorized by action of the Board (and of any other person or body whose action is required) to enter into
this Agreement and to perform its obligations under it, (ii) the execution, delivery and performance of this Agreement by it does not violate any applicable law, regulation, order, judgment or decree or any agreement, arrangement, plan or
corporate governance document (x) to which it is a party or (y) by which it is bound, and (iii) upon the execution and delivery of this Agreement by the parties, this Agreement shall be its valid and binding obligation, enforceable
against it in accordance with its terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors’ rights generally. 

  
 14 

	 	(b)	Executive represents and warrants to the Company that the execution and delivery by Executive of this Agreement do not, and the performance by Executive of
Executive’s obligations hereunder will not, with or without the giving of notice or the passage of time, or both: (i) violate any judgment, writ, injunction, or order of any court, arbitrator, or governmental agency applicable to
Executive; or (ii) conflict with, result in the breach of any provisions of or the termination of, or constitute a default under, any agreement to which Executive is a party or by which Executive is or may be bound. 

 

	15.	Miscellaneous. 

  

	 	(a)	Successors and Assigns. 

  

	 	(i)	This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and permitted assigns and the Company shall require any successor or
assign to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession or assignment had taken place. The Company may not assign or delegate any
rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company. The term “the Company” as used
herein shall include a corporation or other entity acquiring all or substantially all the assets and business of the Company (including this Agreement) whether by operation of law or otherwise. 

 

	 	(ii)	Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by Executive, Executive’s beneficiaries or legal representatives,
except by will or by the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by Executive’s legal personal representatives. 

 

	 	(b)	Right to Counsel. Executive acknowledges that Executive has had the opportunity to consult with legal counsel of Executive’s choice in connection with the
drafting, negotiation and execution of this Agreement and related employment arrangements. 

  

	 	(c)	 Notice. For the purposes of this Agreement, notices and all other communications provided for in the Agreement (including the Notice of
Termination) shall be in writing and shall be deemed to have been duly given when personally delivered or sent by Certified mail, return receipt requested, postage prepaid, addressed to the respective addresses last given by each party to the other,
provided that all notices 

  
 15 

 
to the Company shall be directed to the attention of the Chief Legal Officer of the Company with a copy to the Chief Executive Officer. All notices and communications shall be deemed to have been
received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt. 

 

	 	(d)	Indemnification. Executive shall be indemnified by the Company as provided in Company’s by-laws and Certificate of Incorporation. The obligations under this
paragraph shall survive any termination of the Employment Term. 

  

	 	(e)	Withholding. The Company shall be entitled to withhold the amount, if any, of all taxes of any applicable jurisdiction required to be withheld by an employer
with respect to any amount paid to Executive hereunder. The Company, in its sole and absolute discretion, shall make all determinations as to whether it is obligated to withhold any taxes hereunder and the amount hereof. 

 

	 	(f)	Release of Claims. The termination benefits described in Section 8(d) of this Agreement shall be conditioned on Executive delivering to the Company, a
signed release of claims in the form of Exhibit A hereto within forty-five (45) days or twenty-one (21) days, as may be applicable under the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection
Act, following Executive’s termination date, and not revoking Executive’s consent to such release of claims within seven (7) days of such execution; provided, however, that Executive shall not be required to release any rights
Executive may have to be indemnified by the Company under Section 15(d) of this Agreement. 

  

	 	(g)	Modification. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and
signed by Executive and the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a
waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreement or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party
which are not expressly set forth in this Agreement. 

  

	 	(h)	 Effect of Other Law. Anything herein to the contrary notwithstanding, the terms of this Agreement shall be modified to the extent required to
meet the provisions of the Sarbanes-Oxley Act of 2002, Section 409A, or other federal law, including the Patient Protection and Affordable Care Act of 2010, applicable to the employment arrangements between Executive and the Company. Any delay in
providing benefits or payments, any failure to provide a benefit or payment, or any repayment of compensation that is required under the preceding sentence 

  
 16 

 
shall not in and of itself constitute a breach of this Agreement, provided, however, that the Company shall provide economically equivalent payments or benefits to Executive to the extent
permitted by law. 
  

	 	(i)	Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware applicable to contracts
executed in and to be performed entirely within such State, without giving effect to the conflict of law principles thereof. 

  

	 	(j)	No Conflicts. Executive represents and warrants to the Company that Executive is not a party to or otherwise bound by any agreement or arrangement (including,
without limitation, any license, covenant, or commitment of any nature), or subject to any judgment, decree, or order of any court or administrative agency, that would conflict with or will be in conflict with or in any way preclude, limit or
inhibit Executive’s ability to execute this Agreement or to carry out Executive’s duties and responsibilities hereunder. 

  

	 	(k)	Inconsistencies. In the event of any inconsistency between any provision of this Agreement and any provision of any employee handbook, personnel manual, program,
policy, or arrangement of the Company or its affiliates (including, without limitation, any provisions relating to notice requirements and post- employment restrictions), the provisions of this Agreement shall control, unless Executive otherwise
agrees in a writing that expressly refers to the provision of this Agreement whose control he is waiving. 

  

	 	(l)	Beneficiaries/References. In the event of Executive’s death or a judicial determination of his incompetence, references in this Agreement to Executive shall
be deemed, where appropriate, to refer to his beneficiary, estate or other legal representative. 

  

	 	(m)	Survivorship. Except as otherwise set forth in this Agreement, the respective rights and obligations of the parties hereunder shall survive the Employment Term
and any termination of the Executive’s employment. 

  

	 	(n)	Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or
enforceability of the other provisions hereof. 

  

	 	(o)	Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto and supersedes all prior agreements, if any, understandings and

  

  
 17 

	 	
arrangements, oral or written, between the parties hereto with respect to the subject matter hereof. 

  

	 	(p)	Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement and all of which,
when taken together, will be deemed to constitute one and the same agreement. 

  
 18 

 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly
authorized officer and Executive has executed this Agreement as of the day and year first above written. 
  

			
	 ENDO PHARMACEUTICALS
 HOLDINGS INC.

		
	By:	 	 /s/ DAVID P. HOLVECK

		 	Name: David P. Holveck
		 	Title:   Chief Executive Officer
		
	By:	 	 /s/ IVAN P. GERGEL

		 	Name: Ivan P. Gergel

  
 19 

 EXHIBIT A 
 FORM OF RELEASE AGREEMENT 
 THIS RELEASE AGREEMENT (the
“Release”) is made as of this day of         ,         , by and between Ivan P. Gergel (“Executive”) and Endo Pharmaceuticals Holdings
Inc. (the “Company”). 
  

	1.	 FOR AND IN CONSIDERATION of the payments and benefits provided in the Employment Agreement between Executive and the Company dated as of
October 27, 2011, (the “Employment Agreement”), Executive, for himself or herself, his or her successors and assigns, executors and administrators, now and forever hereby releases and discharges the Company, together with all of its
past and present parents, subsidiaries, and affiliates, together with each of their officers, directors, stockholders, partners, employees, agents, representatives and attorneys, and each of their subsidiaries, affiliates, estates, predecessors,
successors, and assigns (hereinafter collectively referred to as the “Releasees”) from any and all rights, claims, charges, actions, causes of action, complaints, sums of money, suits, debts, covenants, contracts, agreements,
promises, obligations, damages, demands or liabilities of every kind whatsoever, in law or in equity, whether known or unknown, suspected or unsuspected, which Executive or Executive’s executors, administrators, successors or assigns ever had,
now has or may hereafter claim to have by reason of any matter, cause or thing whatsoever; arising from the beginning of time up to the date of the Release: (i) relating in any way to Executive’s employment relationship with the Company or
any of the Releasees, or the termination of Executive’s employment relationship with the Company or any of the Releasees; (ii) arising under or relating to the Employment Agreement; arising under any federal, local or state statute or
regulation, including, without limitation, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Employee
Retirement Income Security Act of 1974, and/or the applicable state law against discrimination, each as amended; relating to wrongful employment termination or breach of contract; or (v) arising under or relating to any policy, agreement,
understanding or promise, written or oral, formal or informal, between the Company and any of the Releasees and Executive; provided, however, that notwithstanding the foregoing, nothing contained in the Release shall in any way
diminish or impair: (a) any rights Executive may have, from and after the date the Release is executed; (b) any rights to indemnification that may exist from time to time under the Company’s certificate of incorporation or bylaws, or
state law or under any other indemnification agreement entered into between Executive and the Company; (c) any rights Executive may have that arise under (or that are preserved by) the Employment Agreement; (d) Executive’s ability to
bring appropriate proceedings to enforce the Release; (e) any rights or claims Executive may have that cannot be waived under applicable law; (f) any claim against any Releasee that brings a claim against Executive (collectively, the
“Excluded Claims”). 

 
Executive further acknowledges and agrees that, except with respect to Excluded Claims, the Company and the Releasees have fully satisfied any and all obligations whatsoever owed to Executive
arising out of Executive’s employment with the Company or any of the Releasees, and that no further payments or benefits are owed to Executive by the Company or any of the Releasees. 

 

	2.	Executive understands and agrees that, except for the Excluded Claims, Executive has knowingly relinquished, waived and forever released any and all rights to any
personal recovery in any action or proceeding that may be commenced on Executive’s behalf arising out of the aforesaid employment relationship or the termination thereof, including, without limitation, claims for backpay, front pay, liquidated
damages, compensatory damages, general damages, special damages, punitive damages, exemplary damages, costs, expenses and attorneys’ fees. 

  

	3.	Executive acknowledges and agrees that Executive has been advised to consult with an attorney of Executive’s choosing prior to signing the Release. Executive
understands and agrees that Executive has the right and has been given the opportunity to review the Release with an attorney of Executive’s choice should Executive so desire. Executive also agrees that Executive has entered into the Release
freely and voluntarily. Executive further acknowledges and agrees that Executive has had at least [twenty-one (21)] [forty-five (45)] calendar days to consider the Release, although Executive may sign it sooner if Executive wishes. In addition, once
Executive has signed the Release, Executive shall have seven (7) additional days from the date of execution to revoke Executive’s consent and may do so by writing to:
            . The Release shall not be effective, and no payments shall be due hereunder, until the eighth (8th) day after Executive shall have executed the Release and returned it to
the Company, assuming that Executive had not revoked Executive’s consent to the Release prior to such date. 

  

	4.	It is understood and agreed by Executive that the payment made to Executive is not to be construed as an admission of any liability whatsoever on the part of the
Company or any of the other Releasees, by whom liability is expressly denied. 

  

	5.	The Release is executed by Executive voluntarily and is not based upon any representations or statements of any kind made by the Company or any of the other Releasees
as to the merits, legal liabilities or value of Executive’s claims. Executive further acknowledges that Executive has had a full and reasonable opportunity to consider the Release and that Executive has not been pressured or in any way coerced
into executing the Release. 

  

	6.	 The exclusive venue for any disputes arising hereunder shall be the state or federal courts located in the State of Delaware, and each of the parties
hereto irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any claim that

  
 Exhibit A-2

	 	
any such proceeding brought in such a court has been brought in an inconvenient forum. Each of the parties hereto also agrees that any final and unappealable judgment against a party hereto in
connection with any action, suit or other proceeding may be enforced in any court of competent jurisdiction, either within or outside of the United States. A certified or exemplified copy of such award or judgment shall be conclusive evidence of the
fact and amount of such award or judgment. 

  

	7.	The Release and the rights and obligations of the parties hereto shall be governed and construed in accordance with the laws of the State of Delaware. If any provision
hereof is unenforceable or is held to be unenforceable, such provision shall be fully severable, and this document and its terms shall be construed and enforced as if such unenforceable provision had never comprised a part hereof, the remaining
provisions hereof shall remain in full force and effect, and the court construing the provisions shall add as a part hereof a provision as similar in terms and effect to such unenforceable provision as may be enforceable, in lieu of the
unenforceable provision. 

  

	8.	The Release shall inure to the benefit of and be binding upon the Company and its successors and assigns. 

IN WITNESS WHEREOF, Executive and the Company have executed the Release as of the date and year first written above. 

 

			
	  
	  	  

	 ENDO PHARMACEUTICALS HOLDINGS INC.
	  	IVAN P. GERGEL

  
 Exhibit A-3Fifth Amendment To The License Agreement

 Exhibit 10.123 
 FIFTH AMENDMENT TO THE LICENSE AGREEMENT 
 This FIFTH AMENDMENT (this “Fifth
Amendment”) to the License Agreement dated July 14, 2004, as thereafter amended (the “Agreement”) by and between Vernalis Development Limited (“Vernalis”) and Endo Pharmaceuticals Inc. (“Endo”), is entered
into as of August 15, 2011 (the “Fifth Amendment Effective Date”) . Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Agreement. 

WHEREAS, pursuant to the Agreement, Vernalis granted to Endo certain rights and licenses to the Product under Vernalis IP; 

WHEREAS, Vernalis wishes to assign the Assigned Patents (as defined below) pursuant to a separate patent assignment document; 

WHEREAS, the Parties wish to further amend the Agreement to reflect the new ownership arrangement of the Assigned Patents; 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, the Parties hereto agree that with effect from the Fifth Amendment Effective Date: 
  

	1.	Notwithstanding the assignment by Vernalis to Endo of the Assigned Patents, all financial terms and rights and obligations of the parties contained in the Agreement
(including without limitation Endo’s obligations to pay milestones and royalties to Vernalis in relation to the Assigned Patents) shall remain unchanged, except as expressly varied by the terms of this Fifth Amendment. For the avoidance of
doubt, neither the assignment of the Assigned Patents as referred to above, nor anything in this Fifth Amendment, shall operate to grant Endo any rights outside the Territory or diminish any of Vernalis’ rights outside the Territory.

  

	2.	Section 1 of the Agreement is hereby amended by inserting the following definition as Section 1.1.5A: 

“Assigned Patents”—the Patent Rights listed in Schedule 12. 

 

	3.	Section 1 of the Agreement is hereby amended by inserting the following definition as Section 1.1.101A: 

“US”—the United States of America. 
  

	4.	Section 1.1.108 of the Agreement shall be deleted in its entirety and replaced with new Section 1.1.108 which shall read as follows: 

“Vernalis Patent Rights”—the Patent Rights which are owned by or licensed to Vernalis at the Closing Date Covering
the Compound or its manufacture or use in the Territory set forth in Schedule 8 and subject to the provisions of Clauses 8.11 and 8.12, any other Patent Rights in the Territory which are owned by or licensed to

  
 1 

 
Vernalis (other than from Endo) during this Agreement which Cover (i) the making, using or Commercialisation of Compound or Product in the form which it exists at the Closing Date; and
(ii) Product Enhancements, to the extent Vernalis has the rights to license the same. When used in Sections 3.1 10.1 and 15.2 (as a constituent part of the definition “Vernalis IP”), and in Sections 12.1, 12.2, 12.5, 12.6, 12.8 and
15.2 “Vernalis Patent Rights” excludes in each case ((i) and (ii)) the Assigned Patents. 
  

	5.	The Agreement is hereby amended by adding new Section 1.2 which shall read as follows: 

References in this Agreement to “sublicense” or “sublicensing” by Endo shall be taken also to mean “license”
or “licensing” by Endo, and related references to “sublicensee” shall be taken also to mean “licensee”, as the context requires. 
  

	6.	The Agreement is hereby amended by adding new Section 3.9 and new Section 3.10 which shall read as follows: 

“3.9 Subject to Clause 3.10, Endo hereby grants Vernalis a royalty-free, fully paid-up, non-terminable, irrevocable, perpetual
license under the Assigned Patents, which shall be sublicensable through multiple tiers: 
 (a) to manufacture, have manufactured
and use the Product in the US solely for the purpose of exporting the Product outside the Territory, which license shall be non-exclusive; 
 (b) subject to Clause 8.10, to conduct or have conducted a Territory Study in the US, which license shall be exclusive; and 
 (c) for all purposes other than to make, have made, use, Commercialise and have Commercialised the Product in the US, which license shall be exclusive. 

3.10 With respect to each Assigned Patent, Vernalis may, at its sole discretion, at any time or times, on written notice to Endo
specifying the relevant Assigned Patent (a) convert the license granted pursuant to Section 3.9 under such Assigned Patent into a non-exclusive license; or (b) whether or not such license is exclusive, or has been converted into a
non-exclusive license, terminate such license, in which case the reference to Assigned Patents in Section 3.9 shall not include such Assigned Patent.” 
  

	7.	The Agreement is hereby amended by adding new Section 12.1A which shall read as follows: 

“12.1A Endo shall have the obligation to prepare, file, prosecute and maintain (with the same or substantially similar coverage) the
Assigned Patents in the US at its own cost and expense and using legal counsel of its own choosing. At Endo’s sole expense (which shall include without limitation the payment by Endo of Vernalis’ reasonable patent attorney charges and
expenses), Vernalis shall provide 

  
 2 

	 	
reasonable assistance to Endo and Endo’s legal counsel by (a) assisting with the reasonable enquiries of Endo’s legal counsel regarding the Assigned Patents and their prosecution
and (b) providing such information as may be in Vernalis’ possession and executing all documents reasonably required to effectuate this Section 12.1A.” 

 

	8.	The Agreement is hereby amended by adding new Section 12.6A which shall read as follows: 

“12.6A Endo shall have the exclusive right, but not the obligation, to, at its own cost and expense, enforce the Assigned Patents
against infringers in the Territory, including, without limitation, to sue and collect damages for infringement, including past infringement or misappropriation, and/or to defend against any Third Party claim of invalidity or unenforceability of any
Assigned Patents (collectively, “Actions”). If requested by Endo, Vernalis shall provide all necessary assistance to Endo in relation to such proceeding. Endo shall, upon demand by Vernalis, indemnify Vernalis against the Costs of such
activity unless Vernalis elects to be separately represented, which separate representation shall be at Vernalis’ own cost and expense. Endo may enter into settlements, stipulated judgments or any other arrangements respecting such infringement
or alleged invalidity in the Territory. If Endo succeeds in any such infringement proceedings whether at trial or by way of settlement, Endo shall be entitled to retain such part of any award of Costs and damages made in such proceedings or
settlement sum as is equal to Endo’s Costs of taking the proceedings and shall be entitled to retain the balance received by Endo less an amount equivalent to the royalties which would have been due to Vernalis on the balance as if they were
Net Sales which amount shall be paid to Vernalis” 
  

	9.	The Agreement is hereby amended by adding new Section 12.8A which shall read as follows: 

“12.8A Should Vernalis receive a certification from a Third Party in the US under the US “Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417), as amended (21 U.S.C. § 355(j)(2)(A)(vii)(IV) for the Assigned Patents Covering the making, having made, using or Commercialisation of a Product, then Vernalis shall immediately give written notice
to Endo of such certification.” 
  

	10.	The Agreement is hereby amended by adding new Section 18.1.3A which shall read as follows: 

“18.1.3A Immediately assign to Vernalis all right, title and interest in and to the Assigned Patents and shall do, or procure the
performance of, all further acts, and execute and deliver (or procure the execution and delivery of) all further documents, that are necessary or desirable to vest in Vernalis the full benefit of all right, title and interest in and to the Assigned
Patents, at Endo’s cost and expense.” 
  

	11.	 The Agreement is hereby amended by inserting in Section 19.1 “, the Assigned

  
 3 

 
Patents” between “the Endo IP” and “ or the Endo Copyright”. 
  

	12.	The Agreement is hereby amended by inserting the list of Patent Rights set forth in Annex 1 to this Fifth Amendment as Schedule 12 to the Agreement.

  

	13.	All terms and conditions of the Agreement not specifically amended herein shall remain unchanged and in full force and effect. 

 

	14.	This Fifth Amendment shall be binding on each Party’s successors and assigns. 

 

	15.	This Fifth Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which shall constitute the same agreement.

 IN WITNESS WHEREOF, the Parties hereto have executed this Fifth Amendment as of the day and year first above written.

  

									
	ENDO PHARMACEUTICALS INC.	 	 	 	VERNALIS DEVELOPMENT LIMITED
					
	By:	 	 /s/ DAVID P. HOLVECK
	 		 	By:	 	 /s/ IAN GARLAND

	Name: David P. Holveck	 		 	Name: Ian Garland
	Title: President and CEO	 		 	Title: Chief Executive Officer

  
 4 

 Annex 1 
 Assigned Patents 
  

					
	Patent No.	 	Issue Date	 	Inventor
	 5,464,864,
	 	7 Nov. 1995	 	King et al.
	 5,616,603
	 	1 April 1997	 	Borrett et al.
	 5,637,611
	 	10 June 1997	 	King et al.
	 5,827,871
	 	27 Oct. 1998	 	King et al.
	 5,962,501
	 	5 October 1999	 	Borrett et al.

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]